将免疫细胞死亡诱导剂和 PD-1 阻断剂作为直肠癌的新辅助疗法。

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-10-17 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2416558

Yan Wang, Liwei Zhao, Zhen Zhang, Peng Liu

引用次数: 0

摘要

免疫肿瘤治疗正转向新辅助治疗。对于胃肠道癌症患者，尤其是局部晚期直肠癌患者，新辅助化疗免疫疗法往往能诱导完全反应，从而避免手术干预。最近的临床试验表明，以奥沙利铂为基础的化疗和PD-1/PD-L1靶向免疫疗法的组合可以在手术前安全进行，并达到治愈目的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer.

Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.